Keyphrases
Clinical Outcomes
100%
Cancer Patients
100%
Clinical Characteristics
100%
CCNE1 Amplification
100%
Gene Aberrations
50%
Solid Tumors
33%
Medical Records
33%
TP53 mutation
33%
Antiangiogenic Therapy
33%
Advanced Malignancies
16%
Anti-angiogenesis
16%
Malignancy
16%
Overall Survival
16%
Survival Benefit
16%
Median Overall Survival
16%
Phase I Trial
16%
Gene Amplification
16%
Phase 1 Clinical Trial
16%
Four Factors
16%
Cyclin E
16%
Advanced Solid Tumors
16%
CCNE1
16%
Upper Normal Limit
16%
Future Therapeutics
16%
Poor Risk
16%
Personalized Approach
16%
Therapeutic Development
16%
Metastasis Diagnosis
16%
Aberrance
16%
Medicine and Dentistry
Solid Malignant Neoplasm
100%
Cancer
66%
Medical Record
66%
Overall Survival
66%
Antiangiogenic Therapy
66%
Metastatic Carcinoma
33%
Clinical Trial
33%
Phase I Trials
33%
Gene Amplification
33%
Antiangiogenic Activity
33%
Cyclin E
33%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Malignant Neoplasm
100%
Overall Survival
66%
Antiangiogenic Therapy
66%
Clinical Trial
33%
Phase I Trials
33%
Cyclin E
33%
Nursing and Health Professions
Solid Malignant Neoplasm
100%
Overall Survival
66%
Medical Record
66%
Antiangiogenic Therapy
66%
Hospital
33%
Clinical Outcome
33%
Cyclin E
33%